Subeschar treatment of burn-wound infection.
Within a 24-month period, 454 patients were admitted with burns (average size, 33% of the total body surface [TBS]). Wound infection developed in 19, who subsequently were treated with subeschar antibiotics. The average burn size in those 19 patients was 63% of the TBS, with an average full-thickness injury of 47%. Five (26%) of the 19 survived, and five others died without evidence of wound infection, giving a would clearance rate of 52.6%. The five surviving patients (average burn size, 59% TBS) underwent excision of infected tissue, with split-thickness cutaneous autograft closure of the burn wound, after the course of subeschar antibiotic infusion. All surviving patients were infected with Pseudomonas aeruginosa. Subeschar infusion of semisynthetic penicillins, therefore, is an effective adjunct in the care of the patient with Pseudomonas burn-wound infection.
D000287:Administration, Topical; D000293:Adolescent; D000328:Adult; D000368:Aged; D000900:Anti-Bacterial Agents / Q000008:administration & dosage*; D002056:Burns / Q000150:complications / Q000188:drug therapy* / Q000601:surgery; D002648:Child; D002675:Child, Preschool; D005260:Female; D006801:Humans; D007223:Infant; D008297:Male; D008875:Middle Aged; D011552:Pseudomonas Infections / Q000188:drug therapy / Q000209:etiology; D014946:Wound Infection / Q000188:drug therapy* / Q000209:etiology / Q000601:surgery
D000900:Anti-Bacterial Agents